Northwire Canada EditionTuesday, August 25, 2026
Northwire
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Other Routine +

Seegnal Announces Letter of Intent with U.S.-Based Care Facility, Marking First Penetration of the American Healthcare Market

Seegnal Eyes U.S. Expansion Amid Regulatory Filing Overhang

Executive Summary
  • Seegnal Inc. announced a Letter of Intent (LOI) with a U.S.-based long-term care provider on May 5, 2026, with public disclosure on May 19, 2026.
  • The pilot program will utilize Seegnal's clinical decision support platform to analyze prescription data for medication-related risks and optimization opportunities.
  • This marks the company's first penetration of the American healthcare market, specifically targeting CMS-certified nursing facilities.
  • Pilot duration is expected between 8 and 12 weeks following receipt of data, with potential for extended evaluation.
  • The engagement focuses on high-risk populations characterized by polypharmacy and adverse drug events without affecting existing clinical workflows.
Material Impact
  • The announcement represents the execution of the strategic vision outlined by new CEO Elad Bibi-Aviv in December 2025 to accelerate U.S. commercial expansion.
  • As an LOI rather than a signed contract or revenue-generating agreement, the immediate financial impact is speculative and incremental.
  • Given the prior guidance on U.S. entry, this news falls under expected execution rather than unexpected market-moving information.
  • The regulatory overhang from the April/May 2026 filing delays and Management Cease Trade Order (MCTO) application creates a significant discount factor for positive business news.
  • While strategically important for long-term growth, the lack of confirmed contract value or revenue recognition limits immediate materiality to stock price appreciation in isolation.
SEGN · Price
Company Overview
  • Seegnal Inc. operates as a global Prescription Intelligence Platform provider with an Israeli operating subsidiary (Seegnal eHealth Ltd.).
  • Flagship Project: The SaaS clinical decision-support platform analyzes prescription data in real-time to identify medication-related risks, optimize prescribing decisions, and reduce adverse drug events.
  • Current Scale: Platform processes over 400,000 prescriptions per day with over 174 million total prescriptions analyzed historically.
  • Deployment: Active deployments include Tel Aviv Sourasky Medical Center (Israel), UAE, UK, Poland, and now the U.S. via pilot program.
  • Certification: Awarded Gold Mark by Standards Institution of Israel in April 2026, holding ISO 13485, ISO 27799, and ISO 27001 certifications.
Read the original news release →

More from Seegnal Inc.